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Abstract 
Preoperative breast radiation therapy (RT) is not a new concept, but older studies 
failed to change practice. More recently, there has been interest in revisiting pre-
operative RT using modern techniques. This current perspective discusses the 
indications, summarises the published literature and then highlights current clinical 
trials, with particular attention to combining with novel drugs and optimising 
associated translational research. 
 
2066 words (excluding abstract) 
Introduction  
Postoperative radiation therapy (RT) is indicated for most patients diagnosed with 
early breast cancer. However, conventional scheduling of breast cancer treatment is 
changing with increasing recognition of advantages of primary systemic therapy. 
Preoperative RT, although investigated in the past, was not demonstrated to be 
sufficiently advantageous for adoption into common practice. However, there have 
been considerable advances in breast RT, including intensity modulated RT (IMRT), 
accelerated partial breast irradiation (APBI), simultaneous integrated boost and (SIB) 
and image guided radiation (IGRT) that could facilitate preoperative RT. In this 
modern setting, preoperative RT may be useful in certain situations, which are 
discussed: (i) downstaging to enable conservation surgery, (ii) facilitating breast 
reconstruction, (iii) facilitating partial breast irradiation, and (iv) aiding translational 
research.  
 
- Downstaging of the tumour to enable conservative surgery  
Compared to mastectomy, women who undergo breast conserving surgery have 
significantly better body image and long-term quality of life scores[1]. For women 
with too locally advanced disease for breast conserving surgery, it may be possible 
to downstage the tumour with primary chemotherapy[2]. However, pathological 
complete response is less likely obtained with chemotherapy in luminal A disease 
and lobular carcinoma[3], than in other subtypes. These women are less likely to 
undergo conservative surgery following chemotherapy[3]. Primary endocrine 
therapy may be an option for these patients, but this practice is still relatively 
uncommon and is usually reserved for unfit patients with short life expectancies. An 
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alternative strategy for women with larger, hormone receptor positive and lower 
grade, breast cancers, could be preoperative RT. This could also be considered as 
salvage treatment for those who have responded less than anticipated to primary 
systemic treatment.  
 
A number of older case series and single arm trials report on preoperative RT with or 
without concomitant chemotherapy[4–19] (Table 1). In those that report on 
receptor status, hormone receptor positive tumours were less likely to achieve 
pathological complete response to chemoradiation (chemoRT) than other 
subtypes[16,17], which is unsurprising given the better complete pathological 
response rates following chemotherapy for higher risk subgroups. 
 
Those reporting on complications in general found more acute toxicity than would 
be expected with modern postoperative breast RT. This is of concern as 
moderate/severe toxicity from preoperative chemoRT could delay surgery and may 
increase surgical complications. Past experience suggests minimum RT-surgery 
interval is 4-6 weeks to minimise complications. Potential contributing factors to the 
increased toxicity include concurrent chemotherapy, and RT protocols and 
techniques using higher total doses, and simple field-based techniques. Modern RT 
techniques may widen the therapeutic ratio: hypofractionated schedules using a 
lower total dose reduce acute toxicity compared with conventional schedules[20], 
intensity modulated RT[21] and simultaneous integrated boost[22] produce more 
homogeneous dose distributions and can reduce acute toxicity and improve long-
term cosmesis. The NeoAPBI trial is exploiting these concepts by sequencing primary 
systemic therapy with accelerated partial breast RT in chemo-resistant cancers[23]. 
 
Patients with hormone receptor positive cancers may benefit from RT in 
combination with endocrine therapy, rather than chemotherapy. This combination 
has been trialed[24]; in the series reported by Bollet et al[24] (n=42) 63% underwent 
breast conserving surgery, while previously been judged ineligible for this. Patients 
underwent surgery at median 8 weeks following completion of RT. Possibly allowing 
more time for maximal tumour regression may increase breast conserving surgery 
rates further. Continued treatment with endocrine therapy may facilitate safely 
increasing this time period, which is investigated in the UK feasibility study Neo-RT.  
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- Facilitating breast reconstruction   
Despite the possibilities for downstaging to enable breast-conserving surgery, some 
patients will need or choose a mastectomy. Many of these patients will also require 
postmastectomy RT and may choose to have breast reconstruction. Scheduling of 
these treatments is challenging, since adding RT to a reconstruction results in a 
higher complication rate[25]. Most guidelines currently recommend RT prior to 
reconstruction[26]. However, this requires two separate surgeries, and there will be 
a delay before reconstruction can be performed. Patient satisfaction and quality of 
life may be improved by immediate reconstruction following mastectomy[27]. 
 
- Current practice for breast reconstruction and radiotherapy 
There are several challenges involved in delivering RT following breast 
reconstruction. Firstly, postoperative healing may cause delay of RT, which could 
impact on oncological outcomes. RT delivery is also potentially more difficult due to 
shape and consistency of the reconstructed breast, especially in case of implant 
reconstruction. Therefore, it may be impossible to obtain required coverage of the 
target whilst respecting dose constraints to organs at risk, resulting in a suboptimal 
plan (see Figure 1). 
 
The current evidence is very limited as there are no randomised trials addressing RT 
timing and reconstruction and most series are small and retrospective. A large 
prospective cohort study has been reported by the Mastectomy Reconstruction 
Outcome Consortium, consisting of 175 patients receiving autologous reconstruction 
and chest wall RT (108 and 67 with immediate versus delayed reconstruction 
respectively)[28]. This showed no difference in complication rates, but lower levels 
of prereconstruction patient satisfaction in the delayed group, although satisfaction 
at one and two years postoperatively was comparable.  
 
An insurance claims-base series of 4781 women who had undergone mastectomy 
and reconstruction (80% with implant-based) and RT showed that patients with 
irradiated implant reconstructions had twice the odds of having a complication and 
11 times the odds of failure compared with irradiated autologous 
reconstruction[29]. The highest probability of implant failure was for RT followed by 
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delayed implant reconstruction, whereas the lowest was for immediate autologous 
reconstruction and postoperative RT.  
 
In summary, it appears that delayed implant–based reconstruction after RT carries 
the greatest side effects, despite possible advantages for technical RT delivery 
before reconstruction. In comparison, toxicity is less with autologous 
reconstructions, but optimal timing of RT is unclear. 
 
- Feasibility of RT prior to mastectomy and reconstruction 
Preoperative RT delivery, followed by mastectomy and immediate breast 
reconstruction may avoid the difficulties described, whilst allowing women to 
benefit from having both surgical steps as one procedure. This sequencing has been 
described in a number of case series, reviewed by Tansley et al[30] in 2013, who 
conclude that oncological outcomes are comparable to standard sequencing. 
However, little published evidence was available at the time of review regarding 
complication rate. A further series of 111 patients published 2016[31] reported a 
rate of primary complications similar to that expected with standard sequencing. 
 
In the UK, the PRADA non-randomised interventional trial will evaluate safety and 
long-term cosmetic outcome of reversing the order of mastectomy with immediate 
reconstruction, with surgery 2-6 weeks after RT.  
 
 
- Facilitating partial breast irradiation 
It is hypothesised that, in appropriately selected low risk patients, local relapse rates 
with partial breast irradiation will be comparable to whole breast RT, and reduced 
irradiated volumes will decrease toxicity. A meta-analysis of published results of 
reported trials to date[32] does not support this. However, the number of trials 
included is limited, and there are several large randomised trials yet to report. 
Preoperative rather than postoperative partial breast irradiation may be 
advantageous.  
 
Oncoplastic techniques can result in difficulty defining the postoperative tumour 
bed; even if surgical clips are inserted as they can be dispersed throughout the 
 6 
breast (see Figure 2[33]). The tumour bed anticipated from the preoperative 
imaging, and the site of the actual target volume, may be significantly different[34]. 
The high interobserver variability reported amongst oncologists delineating the 
clinical target volume for postoperative partial breast irradiation[35] suggests 
difficulty ensuring the tumour bed is accurately targeted. Preoperative RT may 
reduce the risk of geographic miss, and preoperative imaging has been 
demonstrated to correlate with pathological size[36]. 
 
It has been shown that the partial breast clinical target volume may be increased by 
presence of postoperative seroma[37], and seroma size was an independent 
predictor of poor cosmesis in RAPID[38]. Preoperative partial breast RT would avoid 
this issue as well. Treatment volumes in the PAPBI trial of preoperative accelerated 
partial breast RT were significantly smaller (mean PTV 122cm3) than those in 
postoperative partial breast RT studies with comparable mean tumour size[39] 
(mean PTV 296cm3 in the study by Hepel et al[40]). In addition, the tissue receiving 
the highest radiation dose will be removed at surgery following preoperative partial 
breast RT. 
 
- Current preoperative partial breast irradiation studies 
First results of the PAPBI trial have now been published: cosmetic outcome was 
assessed as being good or excellent in 88, 89 and 100% of the 70 patients at 1, 2 and 
3 years respectively[39]. For comparison, cosmesis was rated good/excellent in 71% 
at 3 years in RAPID[41]. At this early time point, efficacy is difficult to comment on 
and further results are awaited. In addition, the PAPBI-2 randomised phase III trial 
opened September 2016[42].  
 
- Facilitating translational studies  
Following the approach of trials of primary systemic treatments, preoperative RT 
studies could facilitate translational research by assessing the effect of radiation 
directly on the tumour. Opportunities to study response to RT in humans are giving 
more reliable information compared to animal models. For example, it has proved 
difficult to produce hormone receptor positive patient-derived xenograft models, 
and to investigate the effects of a competent immune system[43]. This is particularly 
relevant considering RT studies, which are especially challenging following the low 
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local relapse rates, requiring recruitment of very large patient numbers and 
longterm follow-up, to demonstrate an effect. 
 
- Assessment of tumour/normal tissue biology  
Obtaining tissue samples before and after preoperative RT could facilitate research 
on the effects of radiation on both tumour and normal tissues. Greater 
understanding of biological effects of RT on breast tissue may increase the scope for 
personalisation of RT. Research of this nature is currently planned in trials of 
preoperative RT. A secondary goal of the PAPBI trial, alongside the PROBI trial of 
preoperative whole breast RT[44], is to develop a gene expression classifier 
predictive of radiosensitivity[39]. Neo-RT and Trans-PRADA will perform exploratory 
translational research into potential molecular biomarkers of response and into 
radiation-induced immune modulation.  
 
- Assessment of RT/drug combinations 
There is an unmet need for novel RT-drug combinations[45]. Although many 
targeted anticancer agents are now in use, little progress has been made identifying 
those that will synergise most effectively with RT[46]. The UK National Cancer 
Research Institute Clinical and Translational Radiotherapy Research Working 
Group have released a consensus statement that assessment of combination with 
RT should be part of the design of early phase studies in ‘cases with a good biological 
and therapeutic rationale’[45]. For patients with triple negative breast cancer, the 
upcoming phase 1 RadioPARP trial[47] will investigate combination of the PARP 
inhibitor olaparib with RT either preoperatively, or as salvage following incomplete 
response after primary systemic treatment.  This exploits the “BRCAness” trait in 
many of these tumours, with BRCA1 dysfunction causing DNA repair deficiency. 
 
 ‘Window of opportunity’ designs are now explored in ‘phase 0’ trials to expedite 
identification of active agents, with the advantage that tissue samples are obtained 
before and after the treatment of interest and can assess the effects of agents in 
treatment-naïve patients. Further along the drug development pathway, trialling 
RT/drug combinations in the preoperative setting could facilitate seamless phase 
II/III trial design, using pathological complete response as an intermediate 
biomarker. A recent phase 1b trial reported 25% pathological complete response 
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rate with PARP inhibitor veliparib added to preoperative RT and capecitabine in 
rectal cancer[48]; a combination that will be continued in an expanded cohort. 
 
- Imaging biomarkers 
The ability to assess prognostic and predictive tumour variables non-invasively in 
clinical practice is clearly advantageous, however, progress in validating novel 
imaging biomarkers for use in clinical practice has been slow. Studies of 
preoperative therapy have advantages for imaging biomarker validation, permitting 
correlation of imaging features before and during preoperative therapy with 
pathological/molecular endpoints. Increased ability to assess tumour biology with 
imaging could in turn facilitate adaptive RT, using strategies such as dose painting, 
individualised dose and fractionation schedules and combinations with targeted 
agents. 
 
- Conclusion  
Conventional scheduling in breast cancer treatment has been challenged in recent 
years with primary systemic therapy now widely used. The potential advantages of 
delivering RT before surgery are now under investigation, with current and 
upcoming trials aimed at establishing its role in downstaging to enable conservative 
surgery and facilitating breast reconstruction and partial breast irradiation. 
Associated translational research may increase our knowledge of radiation effects in 
breast cancer and tumour tissue biology, facilitate discovery and validation of 
biological/imaging biomarkers and ultimately optimise novel drug-radiation 
combinations. It is too early to speculate on the mature outcomes of these 
initiatives, but the authors of this review support investigation of all these 
approaches within the context of well designed clinical studies. 
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Figure legends 
 
Figure 1 shows a transverse section through a computed tomography (CT) radiation therapy 
planning scan for a patient with bilateral implant reconstructions. This demonstrates the 
challenge to irradiate the chest wall adequately without including unacceptable volumes of 
normal tissue, such as heart, lung and contralateral chest wall. Image provided by Dr O. Kaidar-
Person. 
 
Figure 2 shows the surface rendered image of the CT radiation therapy planning scan for a 
patient who has undergone oncoplastic breast conservation surgery[33]. The red markers 
represent widely scattered tumour bed surgical clips, which may result in a larger boost volume.  
 
 
Footnotes 
1.  The list of trials of preoperative radiotherapy in table 2 was compiled through a 
 combination of literature search, search of clinicaltrials.gov, and personal 
 communication. 
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Tumour 
characteristics 
Total dose 
(dose per 
fraction) 
Concomitant 
chemotherapy  
Response Locoregional 
complications 
Semiglazov
4
 
(1994) 
271 Clinical stage 
IIb-IIIa 
60Gy (2Gy) TMF*/none pCR¶ rate 29.1% 
for those reciving 
concomitant 
chemotherapy; 
19.4% 
radiotherapy 
alone 
Not available 
Touboul
5
 
(1996) 
97 Non-
inflammatory 
breast cancer; 
clinical stage 
IIIa-IIIc 
45Gy (1.8Gy) 
25-30Gy 
boost 
delivered in 
those 
patients not 
undergoing 
surgery 
(34%) 
None 10 year 
locoregional 
control rate 80% 
(76% for those 
not undergoing 
surgery) 
Not available 
Skinner
6
 
(1997) 
30 Non-
inflammatory 
breast cancer; 
clinical stage 
IIb-IIIc 
50Gy (2Gy) 5-fluorouracil pCR rate 17% 30% moist 
desquamation 
Colleoni
7
 
(1998) 
23 Clinical T2-
T4/N0-N1 
50Gy (2Gy) 
10Gy boost 
None pCR rate 8%; 
80% underwent 
breast conserving 
surgery 
Postoperative 
complications 
were ‘frequent’ 
Skinner
8
 
(2000) 
29 Clinical stage 
IIb-III 
45Gy (1.8Gy) Paclitaxel pCR rate 26%  Not available 
Calitchi
9
 
(2001) 
75 Non-
inflammatory 
breast cancer; 
clinical T2-3 
45Gy (1.8Gy) 
15Gy boost 
to internal 
mammary 
nodes 
None pCR rate 11%; 
locoregional 
control rate at 
median follow up 
10 years 88%; 
100% underwent 
breast conserving 
surgery 
Not available 
Formenti
10
 
(2003) 
44 Clinical stage 
IIb-III 
45Gy (1.8Gy) 
14Gy boost 
Paclitaxel pCR rate 16%; 
93% underwent 
modified radical 
mastectomy 
7% grade 3-4 skin 
toxicity 
Lerouge
11
 
(2004) 
120 Non-
inflammatory 
breast cancer; 
clinical stage 
IIIa-IIIc 
45Gy (1.8Gy) 
25-30Gy 
boost 
delivered in 
those 
patients not 
undergoing 
surgery 
(32.5%) 
None 15 year 
locoregional 
control rate 
76.2% 
Not available 
Chakravarthy
12
 
(2006) 
30 Clinical stage 
IIa-IIIb 
46.8Gy 
(1.8Gy) 
Paclitaxel pCR rate 34%; 
43% underwent 
breast conserving 
surgery 
2 patients 
experienced 
grade 3-4 skin 
toxicity 
Bollet
13,14
 
(2006; 2012) 
60  50Gy (2Gy) Vinorelbine and 5-
fluorouracil 
pCR rate 27%; 
69% underwent 
breast conserving 
surgery 
14% grade 3 skin 
toxicity 
 15 
Shanta
15
 
(2008) 
1117 Non-
inflammatory 
breast cancer; 
clinical stage 
IIb-IIIb 
40Gy (2Gy) CMF**/ECF†/FAC†† pCR rate 45.1% ‘Deep 
pigmentation and 
mild to severe dry 
epidermis’, with 
occasional moist 
desquamation 
Alvarado-
Miranda
16
 
(2009) 
112 Clinical stage 
IIb-IIIb; 48% 
ER positive 
50Gy (2Gy) 
10Gy boost  
MTCF‡/GC‡‡ pCR (primary and 
nodal) rate 29.5% 
Not available 
Adams
17
 
(2010) 
105 Clinical stage 
IIb-IIIc; 52% ER 
positive 
45Gy (1.8Gy) 
14Gy boost 
Paclitaxel +/- 
trastuzumab 
pCR rate 34%; 
5 year 
locoregional 
control rate 
95.2% 
Not available 
Matuschek
18
 
(2012) 
315 Clinical T1-
T4/N0-N1 
50Gy (2Gy) 
10Gy boost 
+/- 
hyperthermia 
EC§/CMF/AC§§/ 
mitoxantrone/ 
none 
pCR (primary 
tumour and 
nodal) rate 29.2% 
Not available 
Riet
19
 (2017) 187 Non-
inflammatory 
breast cancer; 
clinical stage 
IIa-IIIb 
45-55Gy 
(2.5Gy) 
None 10% pCR rate; 
30 year 
locoregional 
control rate 89% 
19% 30 day 
postoperative 
complication rate;  
4% grade 3-4 skin 
necrosis 
 Table 1: Case series and trials reporting patients treated in the 1980s,1990s and early 2000s with 
preoperative breast radiotherapy or chemoradiotherapy. *TMF, thiotepa, methotrexate and 5-fluorouracil; 
**CMF, cyclophosphamide, methotrexate and 5-fluorouracil; †ECF, epirubicin, cyclophosphamide and 5-
fluorouracil; ††FAC, 5-fluorouracil, doxorubicin and cyclophosphamide; ‡MTCF, mitomycin C and 5-
fluorouracil; ‡‡GC, gemcitabine and cisplatin; §EC epirubicin and cyclophosphamide; §§AC, doxorubicin and 
cyclophosphamide; ¶pCR, pathological complete response. 
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Title Type of study Patient 
recruitment 
target 
Study design Primary endpoint RT technique 
PAPBI-2 Phase III 
randomised trial 
500 patients Preoperative vs. 
postoperative 
accelerated partial 
breast irradiation 
Cosmetic outcome, 
assessed by digital 
photographs, patient's 
questionnaires and 
specialist's 
questionnaires 
 
Partial breast IMRT 
28.5Gy in 5 
fractions over 1 
week 
NeoAPBI 
01 
Phase II 
randomised trial  
362 patients Primary 
chemotherapy vs. 
primary chemotherapy 
and sequential APBI* 
Breast pathological 
complete response 
rate 
Partial breast 3D-
conformal RT with 
either: 25Gy in 10 
fractions twice a 
day over 5 days 
(maximum 8 days) 
or 25Gy in 8 
fractions daily 
PROBI Phase I/II non-
randomised 
feasibility trial 
94 patients Preoperative whole 
breast radiation 
therapy 
Postoperative 
complications 
Breast (and 
regional lymph 
node) IMRT 46.2 
Gy in 21 fractions 
over 4 weeks, with 
SIB*** to tumour 
to 55.86 Gy 
NeoRT Phase I non-
randomised 
feasibility trial 
43 patients Preoperative breast 
IMRT** followed by 
20 weeks hormonal 
therapy prior to 
surgery 
Proportion of patients 
successfully 
completing 
preoperative radiation 
therapy and hormonal 
therapy followed by 
breast surgery 
Breast IMRT 40Gy 
in 15 fractions over 
3 weeks, with SIB 
to tumour to 48Gy  
RadioPARP Phase I trial 30 patients Preoperative or 
postoperative 
radiation therapy with 
concurrent olaparib 
Maximum tolerated 
dose of olaparib 
Breast RT 50Gy in 
25 daily fractions 
over 5 weeks; 46 
Gy to nodal regions 
in 23 daily fractions 
over 4.6 weeks. SIB 
with IMRT to 
tumour can be 
considered.. 
ABLATIVE Non-randomised 
interventional trial 
25 patients Single dose 
preoperative ablative 
radiation treatment; 
breast conserving 
surgery 6 months 
following completion. 
Breast pathological 
complete response 
rate 
Partial breast 
IMRT, with SIB: 
single fraction 15 
Gy to PTVCTV , 20 
Gy to PTVGT V 
PRADA Non-randomised 
interventional trial 
20 patients Preoperative radiation 
therapy; mastectomy 
and DIEP† flap 
reconstruction 2-6 
weeks following 
completion. 
Presence of open 
breast wound at 4 
weeks after 
mastectomy and DIEP 
flap reconstruction 
Breast (and 
regional lymph 
node) IMRT 40Gy 
in 15 fractions over 
3 weeks 
Table 2: Novel trials involving preoperative radiation therapy currently in the set up phase, or recruiting patients 
(footnote 1). *APBI, accelerated partial breast irradiation; **IMRT, intensity modulated radiation therapy; †DIEP, 
deep inferior epigastric perforator; ***SIB, simultaneous integrated boost. 
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